Diabetes Mellitus and Cardiovascular Dysfunction: A Comprehensive Analysis of Vardenafil's Cardioprotective Effects

Diabetes mellitus is a complex metabolic disorder that exhibits widespread endothelial and cardiac dysfunction, characterized by reduced nitric oxide production. Researchers in Heidelberg, Germany, have provided new insights into the potential benefits of phosphodiesterase-5 inhibitors in mitigating diabetic cardiovascular dysfunction. By up-regulating the nitric oxide-cGMP pathway in the vessel wall and myocardium, vardenafil has shown promise in preventing or reversing impaired left ventricular contractility and endothelial dysfunction in diabetic rats.

Key Takeaways:

• Diabetic rats exhibited increased myocardial and vascular transforming growth factor-beta 1 expression, impaired left ventricular contractility, and reduced endothelial function when compared to non-diabetic controls.
• Chronic treatment with vardenafil (10 mg.kg(-1).day(-1)) for 8 weeks improved diabetic cardiovascular dysfunction in rats by up-regulating the nitric oxide-cGMP pathway.
• Radovits and colleagues demonstrated that impaired vascular cGMP signalling contributes to the development of diabetic vascular and cardiac dysfunction, which can be prevented by chronic phosphodiesterase-5 inhibition.
• The study used a microtip Millar pressure-volume conductance catheter to measure left ventricular pressure-volume relations and calculate indexes of contractility such as E-max and PRSW.
• The researchers found that vardenafil improved endothelium-dependent and independent vasorelaxation in isolated aortae rings, suggesting its potential therapeutic benefits in managing diabetic cardiovascular disease.

Statistics:

• 53% impairment of E-max in diabetic rats compared to non-diabetic controls (P < 0.05)
• 40% impairment of PRSW in diabetic rats compared to non-diabetic controls (P < 0.05)
• 8 weeks duration of chronic vardenafil treatment in rabbits
• 10 mg.kg(-1).day(-1) dose of vardenafil administered orally to diabetic rats

Sources:

• Radovits et al. (2009). The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus. British Journal of Pharmacology, 156(6), 909-919.
• Diabetes Week editors. Copyright 2009, Diabetes Week via NewsRx.com.